Back to today’s briefing

Story perspectives

Trump Administration Study on Mifepristone Sparks Controversy

9/26/2025

24 5

Summary

Story summary

A Trump administration official announced a study on mifepristone's safety, despite abortion approval.
Food and Drug Administration (FDA) may impose guidelines requiring in-person visits to prescribe mifepristone.
Mifepristone accounts for over 60% of U.S. abortions, especially in Republican states where surgical abortions are banned.
A Texas judge is reviewing a lawsuit from anti-abortion groups seeking a nationwide ban on mifepristone.

1 of 1

Story summary

A Trump administration official announced a study on mifepristone's safety, despite abortion approval.
Food and Drug Administration (FDA) may impose guidelines requiring in-person visits to prescribe mifepristone.
Mifepristone accounts for over 60% of U.S. abortions, especially in Republican states where surgical abortions are banned.
A Texas judge is reviewing a lawsuit from anti-abortion groups seeking a nationwide ban on mifepristone.